Market Exclusive

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Entry into a Material Definitive Agreement

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01.

Entry into a Material Definitive Agreement.

As previously reported by Northwest Biotherapeutics, Inc. (the
Company), on March 9, 2017, the Company and the holders (the
Holders) of its 5.00% Convertible Senior Notes due 2017 (the
Notes) entered into a Note Repurchase Agreement (the Repurchase
Agreement). The Notes were issued to an (Indenture), dated August
19, 2014 (the Indenture). On March 17, 2017, the Company executed
a first supplemental indenture to the Indenture, providing that a
default on the Companys payment, performance or other obligations
under the Repurchase Agreement in accordance with its terms also
is also a default under the Indenture and that, if such a default
occurs and is continuing, the principal of all the Notes and
accrued and unpaid interest shall be automatically due and
payable. A copy of the First Supplemental Indenture and the
Repurchase Agreement are attached hereto as Exhibits 10.1 and
10.2, respectively, and are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No. Description
10.1 First Supplemental Indenture, dated March 17, 2017, between
Northwest Biotherapeutics, Inc. and The Bank of New York
Mellon, as trustee
10.2 Repurchase Agreement, dated March 8, 2017, between Northwest
Biotherapeutics, Inc. and the holders of 5.00% Convertible
Senior Notes due 2017

About Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer. Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Recent Trading Information
Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) closed its last trading session down -0.010 at 0.226 with 1,227,914 shares trading hands.

Exit mobile version